A
Aqualung Therapeutics
Developing Immune-Based antibodies to address the development of severe lung inflammation
About Aqualung Therapeutics
Aqualung Therapeutics is a biotechnology company focused on developing innovative treatments for serious inflammatory disorders. The company's core product is a novel anti-inflammatory monoclonal antibody designed to target and mitigate severe inflammation. Aqualung Therapeutics operates in the biopharmaceutical market, primarily serving healthcare providers and patients affected by conditions such as COVID-19, prostate cancer, and radiation-induced lung injury. The business model revolves around research and development, clinical trials, and eventual commercialization of its proprietary biologic therapies. Revenue is generated through funding rounds, partnerships, and future sales of approved treatments. The company is currently seeking $15 million in Series A funding to advance the manufacturing of its lead drug candidate.
Source: Dealroom company dataNews
Open roles
Aqualung Therapeutics in the Tucson ecosystem
The Aqualung Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institutes of Health
Series A1 investor entered at this stage
JSR Life Sciences
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aqualung Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aqualung Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


